ACB Stock Analysis: Buy, Sell, or Hold?
ACB - Aurora Cannabis Inc. Common Shares
$2.67
-0.04 (-1.48%)
▼
5d:
-1.48%
30d:
-18.84%
90d:
-22.16%
BUY
HIGH Confidence
Analysis Updated: Jul 13, 2026 12:00 AM ET
Earnings: Aug 05, 2026
21d
Get Alerted When ACB Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
2 traders called ACB this week
0% bullish • 2 bearish
0% bullish • 2 bearish
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
✅ BUY SIGNAL: ACB shows strong fundamentals and good volume confirmation. Solid entry point despite oversold pricing.
✅ BUY SIGNAL: ACB shows strong fundamentals and good volume confirmation. Solid entry point despite oversold pricing.
In-depth Analysis How we analyze
Valuation Analysis: ACB is currently trading at $2.67, which is considered oversold relative to its 30-day fair value range of $2.69 to $3.19. From a valuation perspective, the stock is trading at a discount (Forward PE: -445.0) compared to its historical average (43.0). At these levels, the market is pricing in 0% annual earnings growth.
Technical Outlook: Technically, ACB is in a strong downtrend. The price is currently testing key support at $2.63. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: The stock shows a mixed technical setup (45/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $6.23 (+133.2%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, ACB is in a strong downtrend. The price is currently testing key support at $2.63. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: The stock shows a mixed technical setup (45/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $6.23 (+133.2%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$2.69 -
$3.19
Company Quality Score
56/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
79.5%
All Signals
- BULLISH: Price oversold vs 30-day range
- NEUTRAL: Mixed technical signals (45/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 133.2% below Wall St target ($6.23)
Trading Range Analysis
30-Day Trading Range
$2.69 -
$3.19
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$2.63
Resistance Level
$2.98
Current Trend
Strong Downtrend
Technical data as of
Jul 13, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-445.00
Wall Street Target
$6.23
(+133.2%)
Revenue Growth (YoY)
5.1%
Earnings Growth (YoY)
-94.7%
Profit Margin
-42.4%
PE vs Historical
-445.0 vs 43.0
CHEAP
Share & Embed Analysis
Last updated: July 14, 2026 7:14 AM ET
Data refreshes hourly during market hours. Next update: 8:14 AM
Data refreshes hourly during market hours. Next update: 8:14 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is ACB showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Drug Manufacturers - Specialty & Generic Stocks
Top-rated stocks in Drug Manufacturers - Specialty & Generic by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NBIX
Neurocrine Biosciences I… |
STRONG BUY
25 analysts |
$198 | 67 BUY |
|
ZTS
Zoetis Inc |
BUY
20 analysts |
$116 | 59 HOLD |
|
UTHR
United Therapeutics Corp… |
STRONG BUY
15 analysts |
$664 | 58 HOLD |
|
LNTH
Lantheus Holdings Inc |
STRONG BUY
13 analysts |
$110 | 51 HOLD |
|
BCRX
BioCryst Pharmaceuticals… |
STRONG BUY
12 analysts |
$22 | 55 HOLD |
Advanced ACB Option Strategies
Professional options setups generated by AI based on today's ACB price and gamma walls.
